OS Therapies (OSTX) Total Non-Current Liabilities (2023 - 2026)
OS Therapies' (OSTX) quarterly Total Non-Current Liabilities came in at $100000.0 in Q1 2026, little changed YoY from $100000.0 in Q1 2025, and little changed on a QoQ basis from $100000.0 in Q4 2025.
OS Therapies (OSTX) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Total Non-Current Liabilities data on file, last reported at $100000.0 in Q1 2026.
- Quarterly Total Non-Current Liabilities changed 0.0% year-over-year to $100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $100000.0, changed 0.0% from the prior year.
- Total Non-Current Liabilities held at $100000.0 in Q1 2026, from $100000.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $100000.0 in Q4 2023 to a low of $100000.0 in Q4 2023.
- A 4-year average of $100000.0 and a median of $100000.0 in 2023 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 0.0% in 2024, down 0.0% in 2024.
- Tracing OSTX's Total Non-Current Liabilities over 4 years: stood at $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025, then changed by 0.0% to $100000.0 in 2026.
- The last three Total Non-Current Liabilities figures came in at $100000.0 (Q1 2026), $100000.0 (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 9.32 Bn |
| 10 | OS Therapies | 19.56 Mn | 19.56 Mn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 100,000.00 |